The CENTAUR phase II clinical drug trial, sponsored by Amylyx Pharmaceuticals and funded by ALS Ice Bucket Challenge donations, began an open label extension, giving people with ALS who completed their trial period an opportunity to continue taking the drug, AMX0035.
All patients who complete the main phase of the study will be eligible for this extension and will receive AMX0035 without placebo. The CENTAUR phase II trial is currently enrolling 132 people with ALS nationwide.
The Association is supporting the CENTAUR phase II trial through ALS Ice Bucket Challenge donations, with a $2.96 million grant in partnership with ALS Finding a Cure.
Read the full press release here.